Inmune Bio, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Inmune Bio, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q3 2024.
  • Inmune Bio, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$12.3M, a 44.1% decline year-over-year.
  • Inmune Bio, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$41.5M, a 53.9% decline year-over-year.
  • Inmune Bio, Inc. annual Operating Income (Loss) for 2023 was -$29.7M, a 14.6% decline from 2022.
  • Inmune Bio, Inc. annual Operating Income (Loss) for 2022 was -$26M, a 11% increase from 2021.
  • Inmune Bio, Inc. annual Operating Income (Loss) for 2021 was -$29.2M, a 138% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$41.5M -$12.3M -$3.76M -44.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 -$37.8M -$9.87M -$3.45M -53.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$34.3M -$11M -$4.59M -71.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$29.7M -$8.38M -$2.74M -48.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$27M -$8.53M -$1.09M -14.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 -$25.9M -$6.41M -$23K -0.36% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$25.9M -$6.42M +$55K +0.85% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$26M -$5.64M +$3.39M +37.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$29.3M -$7.44M +$1.58M +17.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$30.9M -$6.39M +$166K +2.53% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$31.1M -$6.48M -$1.93M -42.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 -$29.2M -$9.03M -$5.82M -181% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-02
Q3 2021 -$23.3M -$9.02M -$4.2M -87.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$19.1M -$6.55M -$4.45M -211% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 -$14.7M -$4.55M -$2.46M -117% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$12.2M -$3.21M -$877K -37.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-03
Q3 2020 -$11.4M -$4.82M -$1.74M -56.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$9.62M -$2.11M -$1.68M -392% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$7.94M -$2.09M -$181K -9.47% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$7.76M -$2.33M -$452K -24.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-04
Q3 2019 -$7.3M -$3.08M -$1.54M -100% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$5.76M -$428K +$5.75M +93.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$11.5M -$1.91M +$935K +32.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$12.4M -$1.88M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 -$1.54M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$6.17M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$2.85M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.